Detailed analysis of bone marrow from patients with ischemic heart disease and left ventricular dysfunction BM CD34, CD11b, and clonogenic capacity as biomarkers for clinical outcomes

Circulation Research

Volumn 115, Issue 10, 2014, Pages 867-874

  Cogle, Christopher R ^a   Wise, Elizabeth ^a   Meacham, Amy M ^a   Zierold, Claudia ^b   Traverse, Jay H ^c   Henry, Timothy D ^c   Perin, Emerson C ^d   Willerson, James T ^d   Ellis, Stephen G ^e   Carlson, Marjorie ^b   Zhao, David X M ^f   Bolli, Roberto ^g   Cooke, John P ^h   Anwaruddin, Saif ⁱ   Bhatnagar, Aruni ^g   Da Graca Cabreira Hansen, Maria ^d   Grant, Maria B ^a   Lai, Dejian ^j   Moyé, Lem ^j   Ebert, Ray F ^k   Olson, Rachel E ^c   Sayre, Shelly L ^j   Schulman, Ivonne H ^l   Bosse, Raphael C ^a   Scott, Edward W ^a   Simari, Robert D ^m   Pepine, Carl J ^a   Taylor, Doris A ^d   more..

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c ABBOTT LABORATORIES   (United States)

^d TEXAS HEART INSTITUTE   (United States)

^e LERNER RESEARCH INSTITUTE   (United States)

^f WAKE FOREST BAPTIST HEALTH   (United States)

^g University of Louisville School of Medicine   (United States)

^h HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

ⁱ UNIVERSITY OF PENNSYLVANIA   (United States)

^j UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^k NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^l UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^m Mayo Clinic College of Medicine   (United States)

more..

Author keywords

Angiogenesis effect; Blood cells; Bone marrow; Myocardial infarction; Stem cells

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CD11B ANTIGEN; CD133 ANTIGEN; CD14 ANTIGEN; CD3 ANTIGEN; CD31 ANTIGEN; CD34 ANTIGEN; CD45 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; VASCULOTROPIN RECEPTOR; BIOLOGICAL MARKER; ITGAM PROTEIN, HUMAN;

ACUTE HEART INFARCTION; ADULT; ANGINA PECTORIS; ARTICLE; BONE MARROW; BONE MARROW TRANSPLANTATION; FEMALE; FLOW CYTOMETRY; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; AGED; BLOOD; BONE MARROW CELL; CFU COUNTING; CLINICAL TRIAL; CONTROLLED STUDY; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; MYOCARDIAL ISCHEMIA; PHYSIOLOGY; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

AGED; ANTIGENS, CD11B; ANTIGENS, CD34; BIOMARKERS; BONE MARROW; BONE MARROW CELLS; COLONY-FORMING UNITS ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; STROKE VOLUME; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84917679165     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.115.304353     Document Type: Article

References (29)

1. Kocher AA, Schuster MD, Szabolcs MJ, Takuma S, Burkhoff D, Wang J, Homma S, Edwards NM, Itescu S. Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyo-cyte apoptosis, reduces remodeling and improves cardiac function. Nat Med. 2001;7:430-436.
2. Fuchs S, Baffour R, Zhou YF, Shou M, Pierre A, Tio FO, Weissman NJ, Leon MB, Epstein SE, Kornowski R. Transendocardial delivery of autolo-gous bone marrow enhances collateral perfusion and regional function in pigs with chronic experimental myocardial ischemia. J Am Coll Cardiol. 2001;37:1726-1732.
3. Jeevanantham V, Butler M, Saad A, Abdel-Latif A, Zuba-Surma EK, Dawn B. Adult bone marrow cell therapy improves survival and induces long-term improvement in cardiac parameters: a systematic review and meta-analysis. Circulation. 2012;126:551-568.
4. Bailey AS, Willenbring H, Jiang S, Anderson DA, Schroeder DA, Wong MH, Grompe M, Fleming WH. Myeloid lineage progenitors give rise to vascular endothelium. Proc Natl Acad Sci USA. 2006;103:13156-13161.
5. Madlambayan GJ, Butler JM, Hosaka K, Jorgensen M, Fu D, Guthrie SM, Shenoy AK, Brank A, Russell KJ, Otero J, Siemann DW, Scott EW, Cogle CR. Bone marrow stem and progenitor cell contribution to neovasculo-genesis is dependent on model system with SDF-1 as a permissive trigger. Blood. 2009;114:4310-4319.
6. Wojakowski W, Tendera M, Michałowska A, Majka M, Kucia M, Maslankiewicz K, Wyderka R, Ochała A, Ratajczak MZ. Mobilization of CD34/CXCR4+, CD34/CD117+, c-met+ stem cells, and mononuclear cells expressing early cardiac, muscle, and endothelial markers into peripheral blood in patients with acute myocardial infarction. Circulation. 2004;110:3213-3220.
7. Massa M, Campanelli R, Bonetti E, Ferrario M, Marinoni B, Rosti V. Rapid and large increase of the frequency of circulating endothelial colony-forming cells (ECFCs) generating late outgrowth endothelial cells in patients with acute myocardial infarction. Exp Hematol. 2009;37:8-9.
8. Suresh R, Chiriac A, Goel K, Villarraga HR, Lopez-Jimenez F, Thomas RJ, Terzic A, Nelson TJ, Perez-Terzic C. CXCR4+ and FLK-1+ identify circulating cells associated with improved cardiac function in patients following myocardial infarction. J Cardiovasc Transl Res. 2013;6:787-797.
9. Losordo DW, Henry TD, Davidson C, et al; ACT34-CMI Investigators. Intramyocardial, autologous CD34+ cell therapy for refractory angina. Circ Res. 2011; 109: 428-436.
10. Quyyumi AA, Waller EK, Murrow J, et al. CD34(+) cell infusion after ST elevation myocardial infarction is associated with improved perfusion and is dose dependent. Am Heart J. 2011; 161: 98-105.
11. Marbán E, Malliaras K. Bone marrow-derived cell therapy after myocar-dial infarction-reply. JAMA. 2013;309:1459-1460.
12. Seeger FH, Tonn T, Krzossok N, Zeiher AM, Dimmeler S. Cell isolation procedures matter: a comparison of different isolation protocols of bone marrow mononuclear cells used for cell therapy in patients with acute myocardial infarction. Eur Heart J. 2007;28:766-772.
13. King A. Stem cells. Could it be TIME to abandon BMCs? Nat Rev Cardiol. 2013;10:8.
14. Traverse JH, Henry TD, Pepine CJ, et al; Cardiovascular Cell Therapy Research Network (CCTRN). Effect of the use and timing of bone marrow mononuclear cell delivery on left ventricular function after acute myocar-dial infarction: the TIME randomized trial. JAMA. 2012;308:2380-2389.
15. Traverse JH, Henry TD, Ellis SG, et al; Cardiovascular Cell Therapy ResearchNetwork. Effect of intracoronary delivery of autologous bone marrow mononuclear cells 2 to 3 weeks following acute myocardial infarction on left ventricular function: the LateTIME randomized trial. JAMA. 2011;306:2110-2119.
16. Perin EC, Willerson JT, Pepine CJ, et al; Cardiovascular Cell Therapy Research Network (CCTRN). Effect of transendocardial delivery of au-tologous bone marrow mononuclear cells on functional capacity, left ventricular function, and perfusion in chronic heart failure: the FOCUS-CCTRN trial. JAMA. 2012; 307: 1717-1726.
17. Zierold C, Carlson MA, Obodo UC, Wise E, Piazza VA, Meeks MW, Vojvodic RW, Baraniuk S, Henry TD, Gee AP, Ellis SG, Moyé LA, Pepine CJ, Cogle CR, Taylor DA. Developing mechanistic insights into cardiovascular cell therapy: Cardiovascular Cell Therapy Research Network Biorepository Core Laboratory rationale. Am Heart J. 2011;162:973-980.
18. Dewald O, Zymek P, Winkelmann K, Koerting A, Ren G, Abou-Khamis T, Michael LH, Rollins BJ, Entman ML, Frangogiannis NG. CCL2/Monocyte Chemoattractant Protein-1 regulates infammatory responses critical to healing myocardial infarcts. Circ Res. 2005;96:881-889.
19. Nahrendorf M, Swirski FK, Aikawa E, Stangenberg L, Wurdinger T, Figueiredo JL, Libby P, Weissleder R, Pittet MJ. The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions. J Exp Med. 2007;204:3037-3047.
20. Tsujioka H, Imanishi T, Ikejima H, Kuroi A, Takarada S, Tanimoto T, Kitabata H, Okochi K, Arita Y, Ishibashi K, Komukai K, Kataiwa H, Nakamura N, Hirata K, Tanaka A, Akasaka T. Impact of heterogeneity of human peripheral blood monocyte subsets on myocardial salvage in patients with primary acute myocardial infarction. J Am Coll Cardiol. 2009; 54: 130-138.
21. Zhao G, Wang S, Wang Z, Sun A, Yang X, Qiu Z, Wu C, Zhang W, Li H, Zhang Y, Zhao J, Zou Y, Ge J. CXCR6 defciency ameliorated myocardial ischemia/reperfusion injury by inhibiting infltration of monocytes and IFN-γ-dependent autophagy. Int J Cardiol. 2013;168:853-862.
22. Assmus B, Iwasaki M, Schächinger V, Roexe T, Koyanagi M, Iekushi K, Xu Q, Tonn T, Seifried E, Liebner S, Kranert WT, Grünwald F, Dimmeler S, Zeiher AM. Acute myocardial infarction activates progenitor cells and increases Wnt signalling in the bone marrow. Eur Heart J. 2012;33:1911-1919.
23. Shelley WC, Leapley AC, Huang L, Critser PJ, Zeng P, Prater D, Ingram DA, Tarantal AF, Yoder MC. Changes in the frequency and in vivo vessel-forming ability of rhesus monkey circulating endothelial colony-forming cells across the lifespan (birth to aged). Pediatr Res. 2012;71:156-161.
24. Wang X, Takagawa J, Lam VC, et al. Donor myocardial infarction impairs the therapeutic potential of bone marrow cells by an interleukin-1-mediat-ed infammatory response. Sci Transl Med. 2011;3:100ra90.
25. Losordo DW, Schatz RA, White CJ, et al. Intramyocardial transplantation of autologous CD34+ stem cells for intractable angina: a phase I/IIa double-blind, randomized controlled trial. Circulation. 2007; 115: 3165-3172.
26. Wang S, Cui J, Peng W, Lu M. Intracoronary autologous CD34+ stem cell therapy for intractable angina. Cardiology. 2010;117:140-147.
27. Vrtovec B, Poglajen G, Lezaic L, Sever M, Socan A, Domanovic D, Cernelc P, Torre-Amione G, Haddad F, Wu JC. Comparison of tran-sendocardial and intracoronary CD34+ cell transplantation in patients with nonischemic dilated cardiomyopathy. Circulation. 2013;128: S42-S49.
28. Fazel S, Cimini M, Chen L, Li S, Angoulvant D, Fedak P, Verma S, Weisel RD, Keating A, Li RK. Cardioprotective c-kit+ cells are from the bone marrow and regulate the myocardial balance of angiogenic cytokines. J Clin Invest. 2006;116:1865-1877.
29. Abbate A, Van Tassell BW, Biondi-Zoccai G, et al. Effects of interleukin-1 blockade with anakinra on adverse cardiac remodeling and heart failure after acute myocardial infarction [from the Virginia Commonwealth University-Anakinra Remodeling Trial (2) (VCU-ART2) pilot study. Am J Cardiol. 2013;111:1394-1400.